Oxidative Medicine and Cellular Longevity

Research Article

Prognostic Value of Oxidative Stress Markers in Patients with Pulmonary Arterial or Chronic Thromboembolic Pulmonary Hypertension

Table 1

Demographic and clinical characteristics of studied patients.


Characteristics	PAH ()	CTEPH ()

Gender (, %)
Female	20 (71)	10 (59)
Male	8 (19)	7 (41)
Age (years)	57 (36.5-68.5)	68 (62-73)
PAH etiology (, %)
IPAH	15 (54)
PAH CHD	9 (32)
PAH CTD	4 (14)
WHO FC (, %)
I	5 (18)	1 (9)
II	14 (50)	11 (65)
III	9 (32)	4 (17)
IV	0 (0)	1 (9)
peakVO₂ (mL/kg/min)	15.35 (12.0-20.3)	17.7 (13.9-19.9)
6MWT (m)	480 (350-563)	390 (240-503)
Right atrium area (cm²)	20 (16.0-31.5)	21 (19-27)
Fluid in pericardium (, %)	3 (11)	4 (24)
NT-pro-BNP (pg/mL)	259.0 (111.0-718.0)	258 (168-476)
RDW (%)	13.9 (13.3-15.8)	14.9 (14.4-16.1)
Troponin I	0.0005 (0.0000-0.0390)	0.0000 (0.0000-0.0005)

IPAH: idiopathic pulmonary arterial hypertension; PAH CHD: pulmonary arterial hypertension associated with congestive heart defect; PAH CTD: pulmonary arterial hypertension associated with connective tissue disease; CTEPH: chronic thromboembolic pulmonary hypertension; WHO FC: World Health Organization Functional Class; peakVO₂: peak oxygen consumption; 6MWT: 6-minute walking test; NT-pro-BNP: N-terminal B-type natriuretic peptide; RDW: red blood cell distribution width.